Management of Craniosynostosis in Lethal Perinatal Hypophosphatasia

J Craniofac Surg. 2023 Nov-Dec;34(8):2422-2425. doi: 10.1097/SCS.0000000000009641. Epub 2023 Aug 23.

Abstract

Although perinatal lethal hypophosphatasia (HPP) was once a disease with a universally poor prognosis, it has now become a rare but treatable condition with the advent of enzyme replacement therapy with asfotase alfa. As a result, a greater population of patients with perinatal HPP are presenting with abnormal head shape and craniosynostosis. The authors present here 3 cases of perinatal lethal HPP, 1 treated with traditional open cranial vault remodeling and 2 treated utilizing distraction osteogenesis techniques. All patients demonstrated outcomes comparable to those previously reported with traditional observation or open cranial vault repair. Thorough consideration and discussion between the surgical team and patient's family is needed to determine a treatment plan that best addresses the goals of patient and family in light of recent advances in medical treatment in this rare patient population in which surgical interventions were previously nearly impossible. This article further supports the safety and efficacy of surgical intervention and explores the utility of distraction osteogenesis to address craniosynostosis in this patient population.

MeSH terms

  • Alkaline Phosphatase
  • Craniosynostoses* / surgery
  • Enzyme Replacement Therapy / methods
  • Female
  • Humans
  • Hypophosphatasia* / chemically induced
  • Hypophosphatasia* / surgery
  • Osteogenesis, Distraction*
  • Pregnancy

Substances

  • Alkaline Phosphatase

Supplementary concepts

  • Hypophosphatasia, Perinatal Lethal